AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 261 min read$ANL

Ye Xiaofeng sold $165K of ANL

Ye Xiaofeng (CFO) sold 11,667 shares of Adlai Nortye Group Ltd. (ANL) at an average of $14.11 ($13.98–$14.25, $0.16M total) across 2 trades over 2026-08-24 to 2026-08-26.

Original reporting
SEC EDGAR · Ye Xiaofeng
Published Aug 26, 2026, 8:28 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 26, 2026, 8:57 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ANL
Neutral
high confidence
Mentioned
$ANL
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ANLNeutralLow
01

Why it matters

The disclosed sale represents a modest reduction in insider stake, with minimal effect on market perception.

02

Market read

Limited relevance; primarily of interest to shareholders monitoring insider activity.

03

What to watch

Potential upcoming corporate actions or earnings that prompted the insider to adjust holdings.

Relevance 4/10Novelty 4/10Timing: filed 2026-08-26

Background

Form 4 filings disclose insider trades and are required by the SEC. Small insider sales are common and usually not market‑moving.

Company-level read

Ticker impact

$ANLNeutralHigh confidence
Context

CFO Ye Xiaofeng sold 11,667 shares for $164,635 in an open‑market transaction filed on 2026‑08‑26.

Expected impact

No significant price impact expected.

Evidence & confidence

The sale size is small relative to total shares outstanding and typical insider trading volumes.

Market effects

Sector

None; transaction is company‑specific.

Regional

None; limited to ANL shareholders.

Global

None

Counterpoint

What could challenge this read

The sale could be interpreted as insider confidence if viewed as routine portfolio rebalancing.

Key entities

  • Company
    Adlai Nortye Group Ltd.

    Issuer of the stock traded under ticker ANL.

  • Individual
    Ye Xiaofeng

    Chief Financial Officer of ANL who executed the sale.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ANL insider trading history →

Related articles

OCT 16
$ANLMed

Adlai Nortye collaborates with Lilly and Merck KGaA

Adlai Nortye Group (Nasdaq: ANL) has partnered with Eli Lilly (NYSE: LLY) and Merck KGaA (MRK: DE) for clinical trials involving cetuximab (Erbitux). The collaboration supports Adlai Nortye's Phase I trial for AN4035, evaluating it as a monotherapy and with cetuximab in specific cancer patients. The trial is sponsored by Adlai Nortye.

thepharmaletter.com2 min
OCT 15
$ANLLowAI 8/10

Adlai Nortye Strikes Global Clinical Collaboration with Lilly and Merck for AN4035 Combination Trial

Adlai Nortye (ANL) has partnered with Lilly and Merck KGaA for a global Phase I trial of AN4035, a CEACAM5-targeting ADC. Lilly and Merck will supply cetuximab for free. ANL's stock has a Buy rating with a $31 target, but Spark rates it Neutral due to financial risks and bearish trends. ANL focuses on precision oncology, targeting RAS-addicted cancers.

tipranks.com2 min
OCT 15
$ANLMed

Adlai Nortye lines up Lilly, Merck KGaA for AN4035 trial

Adlai Nortye (ANL) partnered with Lilly (LLY) and Merck KGaA for a trial of its cancer drug AN4035. Lilly and Merck will supply cetuximab for free in the US, Australia, and China. AN4035 targets colorectal, pancreatic, and lung cancers. ANL's stock is down 25.96% over 20 days, closing at $11.61 on the announcement day.

financial-news.co.uk2 min
AUG 14
$ANLMedAI 8/10

Adlai Nortye Ltd. Reports Unaudited First Half 2026 Financial Results and Highlights Recent Operational Progress

Adlai Nortye Ltd. (NASDAQ: ANL) reported unaudited first-half 2026 results and pipeline updates. It said enrollment is ongoing for Phase I AN9025 in QD and QW arms, and it received Australia HREC approval for Phase I AN4035. Cash and short-term investments were $231.9M at June 30, 2026. Net loss fell to $5.3M; revenue rose to $13.1M.

finanznachrichten.de6 min